Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | MPL | P40238 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24616544 | 0.81 | NPC1 (0.38) | SMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL20297775 | 0.81 | HTT (0.46) | SMN1; SMN2HTTALDH1A1PDPK1CYP3A4 | |
| SCHEMBL30807901 | 0.80 | HPGD (0.43) | SMN1; SMN2HTTALDH1A1PDPK1MPL | |
| SCHEMBL18343884 | 0.80 | HPGD (0.43) | SMN1; SMN2HTTALDH1A1PDPK1MPL | |
| SCHEMBL29344100 | 0.78 | TLR8 (0.38) | — | |
| SCHEMBL21091402 | 0.77 | PDPK1 (0.49) | SMN1; SMN2HTTALDH1A1LMNAPDPK1 | |
| SCHEMBL29885344 | 0.77 | PDPK1 (0.49) | SMN1; SMN2HTTALDH1A1LMNAPDPK1 | |
| SCHEMBL289153 | 0.77 | ALDH1A1 (0.49) | SMN1; SMN2HTTALDH1A1LMNAPDPK1 | |
| SCHEMBL30339919 | 0.77 | ALDH1A1 (0.49) | SMN1; SMN2HTTALDH1A1LMNAPDPK1 | |
| SCHEMBL23985953 | 0.77 | SMN1; SMN2 (0.47) | SMN1; SMN2HTTALDH1A1LMNAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528818-B2 | Compositions and methods for inhibition of RAS | LEIDOS BIOMEDICAL RESEARCH, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250270225-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | NNSA | 2025-08-28 | — | — | US | disclosed |
| EP-4570805-A1 | TRICYCLIC COMPOUNDS AND MEDICAL USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-06-18 | — | — | EP | disclosed |
| CN-119431406-A | Tricyclic compounds and medical uses thereof | 正大天晴药业集团股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240300964-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. | 2024-09-12 | — | — | US | disclosed |
| EP-4373822-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | Theras Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2024-05-02 | — | — | US | disclosed |
| CN-117916238-A | Compositions and methods for inhibiting RAS | 瑟拉斯有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2024032747-A1 | TRICYCLIC COMPOUNDS AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2024-02-15 | — | — | WO | disclosed |
| EP-4144732-A1 | BENZOTHIAZOLYL BIARYL COMPOUND, AND PREPARATION METHOD AND USE | Shanghai Ringene BioPharma Co., Ltd. (CN) | 2023-03-08 | — | — | EP | disclosed |
| WO-2023004102-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022148422-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022095960-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | 泰励生物科技（上海）有限公司 | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270225-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | SMN1; SMN2 2490/4885HTT 1204/4885ALDH1A1 3077/4885 |
| US-20240300964-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | SMN1; SMN2 2490/4885HTT 1204/4885ALDH1A1 3077/4885 |
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | KRAS, NRAS, G3BP1 | SMN1; SMN2 1542/4885HTT 2781/4885ALDH1A1 3389/4885 |
| US-12528818-B2 | Compositions and methods for inhibition of RAS | KRAS, NRAS, HRAS | SMN1; SMN2 654/4885HTT 2171/4885ALDH1A1 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.